by Thomas Derrick Hull, PhD | Jul 26, 2022 | Uncategorized
At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial Presented on Tuesday 26th July 2022 | 12.30pm EST | 5.30pm UK Thomas D Hull,...
by David Mathai, MD and Scott Lee, MD | Jul 12, 2022 | Uncategorized
Mapping consent practices for outpatient psychiatric use of ketamine Presented on Tuesday 12th July 2022 | 12.30pm EST | 5.30pm UK David S Mathai, Scott M Lee, Victoria Mora, Kelley C O’Donnell, Albert Garcia-Romeu, Eric A Storch. J Affect Disord. 2022 Sep...
by Prof David J.R. Foster PhD | Jun 28, 2022 | Uncategorized
Population pharmacokinetics and pharmacodynamics of the therapeutic and adverse effects of ketamine in patients with treatment-refractory depression Presented on Tuesday, 28 June 2022 | 10:00pm (UK time)| 5:00pm (NYC time) | Wednesday, 29 June 2022, 6:30am (Adelaide,...
by Radhika Rawat, MD, PhD | Jun 14, 2022 | Uncategorized
Ketamine activates adult-born immature granule neurons to rapidly alleviate depression-like behaviors in mice Presented on Tuesday 14th June 2022 | 05:30 PM (UK time) | 12:30 PM (EDT NY time) | 09:30 AM (PDT LA time) Radhika Rawat, Elif Tunc-Ozcan, Tammy L. McGuire,...
by Sara de la Salle, PhD | May 24, 2022 | Uncategorized
Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression Presented on Tuesday 24th May 2022 | 05:30 PM (UK time) | 12:30 PM (EDT NY time) | 09:30 AM (PDT LA time) Sara de la Salle,...
by David Samuel Mathai, MD | May 10, 2022 | Uncategorized
Toward Synergies of Ketamine and Psychotherapy Presented on Tuesday 10th May 2022 | 05:30 PM (UK time) | 12:30 PM (EDT NY time) | 09:30 AM (PDT LA time) David S Mathai, Victoria Mora, Albert Garcia-Romeu. Front Psychol. 2022 Mar 25;13:868103. doi:...
